Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma.
Authors
Jonathan Matthew Hernandez
National Cancer Institute, Bethesda, MD
Jonathan Matthew Hernandez , M. Cecilia Monge B. , Jack Victory , Cathleen Hannah , Kathleen Smith , Emily Smith , Leila Sarvestani , Tracey Pu , Carolina Larrain , Kenneth Luberice , Lindsay Friedman , Ashley Rainey , Hannah Stepp , Alyssa Eade , Andrew M. Blakely , Jeremy Davis , Sofia Gameiro , Jeffrey Schlom , James L. Gulley , Tim F. Greten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT05286814
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS586)
DOI
10.1200/JCO.2024.42.3_suppl.TPS586
Abstract #
TPS586
Poster Bd #
P15
Abstract Disclosures
Similar Posters
First Author: Valerie Boige
Poster
2019 Gastrointestinal Cancers Symposium
ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
First Author: Zev A. Wainberg
Poster
2018 ASCO Annual Meeting
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
First Author: Zev A. Wainberg
Poster
2017 Gastrointestinal Cancers Symposium
A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.
First Author: Naminatsu Takahara